Boulder’s Arpeggio Bioscience raises $17M Series A to bolster drug trials
BOULDER — Arpeggio Bioscience Inc., a preclinical-stage pharmaceutical company founded by University of Colorado Boulder doctoral program graduates, has raised a $17 million Series A fundraising round that will allow the company to scale its early drug trials.
San Francisco venture-capital investor Builders VC led the Series A, which followed a $3.2-million seed round in 2020.
Arpeggio has developed an artificial-intelligence-enabled platform for drug discovery that examines “what’s wrong with the entire cellular network that defines a disease” and applies potential treatments, Arpeggio co-founder and CEO Joey Azofeifa told BizWest.
The…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Tilled Inc., a Boulder payment-facilitation technology company, recently completed a $12.5 million investment round, bringing…
-
Brightwave, Boulder-based AI technology company is “swinging for the fences,” after raising $21 million to…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
